MiMedx Group, Inc.
MDXGHealthcareNASDAQBiotechnology
Scan Results
Daily timeframePart of the healthcare sector, MiMedx Group, Inc. (MDXG) is listed under Biotechnology. The company carries a $570.6M market cap, placing it firmly in the small-cap category. The company processes the human placental tissues membrane, and umbilical cord and the placental disc utilizing its patented and proprietary PURION process to produce allografts that retains the tissue's inherent biological properties and regulatory proteins, including cytokines, chemokines, and growth factors.
Market Cap
$570.6M
Beta
1.17
P/E (TTM)
97.75
P/E (Fwd)
37.24
EPS (TTM)
$0.04
EPS (Fwd)
$0.10
ROE
2.9%
ROA
1.9%
Cash
$135.8M
Total Debt
$17.2M
Free CF
$41.4M
52W Change
-41.9%
Annual Financials
Cash vs Debt
Where MDXG stands vs its 150-day and 200-day moving averages
As of the October 20, 2026 close, MDXG finished 7.35% above its 150-day moving average ($4.08) and 0.23% above its 200-day moving average ($4.37). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is MDXG overbought or oversold?
At the October 20, 2026 close, MDXG's RSI(14) was 33.7, in neutral territory (between 30 and 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
The balance sheet looks solid with $135.8M in cash comfortably exceeding the $17.2M debt load. A net cash position generally provides financial flexibility during uncertain economic periods. Free cash flow comes in at $41.4M, providing flexibility for reinvestment, buybacks, or dividends. Consistent free cash flow generation is often considered a sign of operational health. ROE of 2.9% points to modest capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. ROA of 1.9% is on the lower side, which is common in asset-heavy industries. Revenue has grown from $267.8M (2022) to $418.6M (2025), reflecting a 56% increase over the period.
With cash comfortably exceeding debt, MDXG has financial flexibility that may help navigate uncertain periods. At over 50x earnings, MDXG carries valuation risk — any slowdown in growth expectations could lead to meaningful price adjustments. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence MiMedx Group, Inc.'s trajectory.